Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.53 |
| ▸ | HPGD | P15428 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 7/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205363 | 0.93 | CYP3A4 (0.48) | CYP3A4MAPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6226169 | 0.86 | KMT2A (0.56) | SMN1; SMN2KDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL3444705 | 0.86 | CDK1 (0.64) | KDM4EKMT2ANPC1MAPTTDP1 | |
| SCHEMBL3445703 | 0.82 | CDK2 (0.60) | CYP3A4MAPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3446716 | 0.82 | CDK2 (0.67) | MAPK1KDM4ENPC1MAPTTDP1 | |
| SCHEMBL3445038 | 0.80 | CDK1 (0.68) | CYP3A4MAPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3445288 | 0.79 | CDK1 (0.57) | CYP3A4MAPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3445290 | 0.79 | CDK1 (0.57) | CYP3A4MAPK1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3444679 | 0.78 | CDK1 (0.69) | CYP3A4MAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3445122 | 0.78 | CDK1 (0.69) | CYP3A4MAPK1SMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | CYP3A4 2872/4885MAPK1 184/4885SMN1; SMN2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.